CONSIDERATION IN RETURN FOR CONSENT: ETHICS OF PAYMENTS MADE TO AND BY CLINICAL TRIAL SUBJECTS
Keywords:
Ethics, clinical trials, payment, informed consent, considerationAbstract
Clinical trials are less known about in India, especially by our rural population. There seems
to be a dire need for creating public awareness and understanding of clinical trials/research
and consequently the importance of informed consent, and other pre-requisites of conducting
a clinical trial in India. This being the case, this paper shall specifically deal with the ethical
and legal concerns that may arise out of paying clinical trial patients. This paper shall deal
with the problems with informed consent in paediatric trials, trials relating to substance
users and trials relating to other people incapable of giving consent. This paper shall also
deal with the question as to whether money or other considerations in the form of incentives
can be said to cloud the judgement of trial subjects while giving consent, thereby making it
an uninformed consent. This paper shall also deal with the ethical aspect of accepting
donations, etc. as criteria for accepting clinical trial subjects.
References
1. National Ethical Guidelines for Biomedical and Health Research involving Human Participant, 5.0 (Roli Mathur ed., 2017), https://ethics.ncdirindia.org//asset/pdf/ICMR_National_ Ethical_Guidelines.pdf (last visited Mar 31, 2021).
2. Furkhan Ali et al., Consent in current psychiatric practice and research: An Indian perspective, 61 Indian J Psychiatry S667–S675 (2019).
3. National Ethical Guidelines for Biomedical and Health Research involving Human Participant, supra note 1.
4. Mental Healthcare Act, No. X of 2017, India code , http://egazette.nic.in/WriteReadData/ 2017/175248.pdf (last visited Mar 28, 2021).
5. Luke Gelinas et al., A Framework for Ethical Payment to Research Participants , New England (last visited Mar 31, 2021).
6. National Ethical Guidelines for Biomedical and Health Research involvi ng Human Participant, supra note 1 at 2.5.1.
7. Gelinas et al., supra note 6 at 769.
8. M. Stones & J. McMillan, Payment for participation in research: a pursuit for the poor? , 36
9. Gelinas et al., supra note 6 at 769.
10. Rosamond Rhodes, Rethinking research ethics , 5 AM J Bioeth 7–28 (2005); John Harris, Scientific research is a moral duty, 31 Journal of Medical Ethics 242–248 (2005).
11. Claudine G Jennings et al., Does offering an incentive paymen t improve recruitment to clinical trials and increase the proportion of socially deprived and elderly participants?, 16 Trials 1–9, 8–9 (2015).
12. Stones and McMillan, supra note 9 at 36.
13. Christine Grady, Payment of clinical research subjects , 115 J Clin Invest 1681–1687, 1686 (2005).
14. Id. at 1686.
15. Lyn Horn, Payment of clinical trial participants , 98 South African Medical Journal 93–94, 94 (2008).
16. Jennifer Koen et al., Payment of trial participants can be ethically sound: Moving past a flat rate, 98 South African Medical Journal 4, 928 (2008).
17. Emily A. Largent et al., Money, Coercion, and Undue Inducement: A Survey of Attitudes about Payments to Research Participants, 34 IRB 1–8, 7–8 (2012).
18. VeenaD Joshi et al., Public awareness and perception of clinical trials: Quantitative study in Pune, 4 Perspectives in Clinical Research 169 (2013).
19. Peoples’ Union for Democratic Rights v. Union of India and others, 1983 SCR (1) 456 (India).
20. Sandhya Srinivasan & Sachin Nikarge, Ethical concerns in clinical trials in India: an investigation 10 (2009).
21. Jennings et al., supra note 13 at 7–8.
22. Largent et al., supra note 20.
23. National Ethical Guidelines for Biomedical and Health Research involving Human Participant, supra note 1.
24. Grady, supra note 15 at 1686.
25. Id. at 1686.
26. Id. at 1686.
27. Pikee Saxena & Rohit Saxena, Clinical Trials: Changing Regulations in India , 39 Indian J Community Med 197–202 (2014).
28. Clinical Trials in India (Phase -I/II/III/IV)| Morulaa, (2015), https://morulaa.com/indian -medical- device-market/clinical-trials-in-india-document-requirements/ (last visited Apr 1, 2021).
29. Saxena and Saxena, supra note 30.
30. See e.g. Joyce Baldwin, Demand grows for early access to promising cancer drugs , 94 J Natl Cancer Inst 1668–1670 (2002).
31. Srinivasan and Nikarge, supra note 23 at 10.
32. Shobha Misra, Randomized double blind placebo control studies, the “Gold Standard” in intervention based studies, 33 Indian J Sex Transm Dis AIDS 131–134 (2012).
33. Sharoon David & Paras B. Khandhar, Double-Blind Study , in Stat pearls (2021), http://www.ncbi.nlm.nih.gov/books/NBK546641/ (last visited Apr 1, 2021).
34. Misra, supra note 38.
35. David and Khandhar, supra note 39.
36. Misra, supra note 38.
